--- title: Sinocompound extends non-PGM catalyst range through new licensing agreement with Dalhousie University description: Sinocompound has announced a new licensing agreement for a range of novel non-platinum group metal (non-PGM) catalysts from Dalhousie University, Canada. image: https://news.lifesciencenewswire.com/hubfs/Prof.%20Mark%20Stradiotto.jpg --- [![Life Science Newswire 2](https://news.lifesciencenewswire.com/hs-fs/hubfs/Life%20Science%20Newswire%202.png?width=203&height=60&name=Life%20Science%20Newswire%202.png "Life Science Newswire 2")](https://lifesciencenewswire.com/) - [Newsroom](https://news.lifesciencenewswire.com/newsroom) - [Back to the main site](https://lifesciencenewswire.com/) ![LSNewswire-main-header-banner-v2-1](https://news.lifesciencenewswire.com/hubfs/LSNewswire-main-header-banner-v2-1.jpg "LSNewswire-main-header-banner-v2-1") # Newsroom #### Categories ![Arrow](https://cdn2.hubspot.net/hubfs/3842749/ps4-Pack/sidebar.svg "Arrow") #### Subscribe![](https://cdn2.hubspot.net/hubfs/3842749/ps4-Pack/subscribe-rss-button.svg) ![](https://cdn2.hubspot.net/hubfs/3842749/ps4-Pack/close-button.svg) ### Choose a Category - [Agriculture (1)](https://news.lifesciencenewswire.com/newsroom/tag/agriculture) - [Analytical Chemistry (42)](https://news.lifesciencenewswire.com/newsroom/tag/analytical-chemistry) - [Biomanufacturing (34)](https://news.lifesciencenewswire.com/newsroom/tag/biomanufacturing) - [biopharma (20)](https://news.lifesciencenewswire.com/newsroom/tag/biopharma) - [Bioprocessing (15)](https://news.lifesciencenewswire.com/newsroom/tag/bioprocessing) - [Biotechnology (244)](https://news.lifesciencenewswire.com/newsroom/tag/biotechnology) - [Cell Culture (9)](https://news.lifesciencenewswire.com/newsroom/tag/cell-culture) - [Clinical Diagnostics (36)](https://news.lifesciencenewswire.com/newsroom/tag/clinical-diagnostics) - [clinical research (6)](https://news.lifesciencenewswire.com/newsroom/tag/clinical-research) - [Clinical Research & Trials (108)](https://news.lifesciencenewswire.com/newsroom/tag/clinical-research-trials) - [Computing & Technology (62)](https://news.lifesciencenewswire.com/newsroom/tag/computing-it) - [Corporate, Finance & Investor (283)](https://news.lifesciencenewswire.com/newsroom/tag/corporate-finance-investor) - [COVID-19 (86)](https://news.lifesciencenewswire.com/newsroom/tag/covid-19) - [Diagnostics & Hospital Laboratory (35)](https://news.lifesciencenewswire.com/newsroom/tag/diagnostics-hospital-laboratory) - [Drug Discovery & Development (147)](https://news.lifesciencenewswire.com/newsroom/tag/drug-discovery-development) - [Energy & Environment (15)](https://news.lifesciencenewswire.com/newsroom/tag/energy-environment) - [excipients (1)](https://news.lifesciencenewswire.com/newsroom/tag/excipients) - [Food & Beverage (8)](https://news.lifesciencenewswire.com/newsroom/tag/food-beverage) - [General Chemistry (7)](https://news.lifesciencenewswire.com/newsroom/tag/general-chemistry) - [General Laboratory (55)](https://news.lifesciencenewswire.com/newsroom/tag/general-laboratory) - [General Science (5)](https://news.lifesciencenewswire.com/newsroom/tag/general-science) - [Healthcare (132)](https://news.lifesciencenewswire.com/newsroom/tag/healthcare) - [Hospital Management (6)](https://news.lifesciencenewswire.com/newsroom/tag/hospital-management) - [Life Science (26)](https://news.lifesciencenewswire.com/newsroom/tag/life-science) - [Manufacturing (2)](https://news.lifesciencenewswire.com/newsroom/tag/manufacturing) - [Materials Science (2)](https://news.lifesciencenewswire.com/newsroom/tag/materials-science) - [Medical Devices & Technology (25)](https://news.lifesciencenewswire.com/newsroom/tag/medical-devices-technology) - [Microbiology & Infection Control (18)](https://news.lifesciencenewswire.com/newsroom/tag/microbiology-infection-control) - [Microscopy & Imaging (47)](https://news.lifesciencenewswire.com/newsroom/tag/microscopy-imaging) - [Nanotech (2)](https://news.lifesciencenewswire.com/newsroom/tag/nanotech) - [Omics & Genetics (86)](https://news.lifesciencenewswire.com/newsroom/tag/omics-genetics) - [Pathology (5)](https://news.lifesciencenewswire.com/newsroom/tag/pathology) - [Pharma (114)](https://news.lifesciencenewswire.com/newsroom/tag/pharma) - [Pharmacy (4)](https://news.lifesciencenewswire.com/newsroom/tag/pharmacy) - [Research (47)](https://news.lifesciencenewswire.com/newsroom/tag/research) - [Veterinary (5)](https://news.lifesciencenewswire.com/newsroom/tag/veterinary) - [Water (8)](https://news.lifesciencenewswire.com/newsroom/tag/water) See all ### Subscribe to Email Updates - ##### SHARE - - - # [Sinocompound extends non-PGM catalyst range through new licensing agreement with Dalhousie University](https://news.lifesciencenewswire.com/newsroom/sinocompound-extends-non-pgm-catalyst-range-through-new-licensing-agreement-with-dalhousie-university) April 13, 2022 [![Prof. Mark Stradiotto](https://news.lifesciencenewswire.com/hs-fs/hubfs/Prof.%20Mark%20Stradiotto.jpg?width=241&name=Prof.%20Mark%20Stradiotto.jpg)](https://drive.google.com/file/d/1IhNVrD-7vMrEDj5h5WukGyg4-s1DbxyO/view?usp=sharing)Sinocompound Catalysts Co., Ltd, has announced a new licensing agreement for a range of novel non-platinum group metal (non-PGM) catalysts from Dalhousie University, Canada. These advanced non-PGM catalysts contain a 'DalPhos' phosphine-based ancillary ligand, allowing access to a range of challenging C-N/C-O cross-couplings. DalPhos ligands and their preformed Ni catalysts will be scaled-up, manufactured and supplied by Sinocompound, further building out the company’s portfolio of non-PGM catalysts alongside their extensive range of PGM catalysts and associated ligands. The DalPhos ligands were developed by Prof. Mark Stradiotto and his research team at the Department of Chemistry, Dalhousie University. Sinocompound has an extensive portfolio of catalysts and the ability to scale up production rapidly as required. Their established team of metal catalyst and ligand experts work in partnership with customers to help them find solutions to challenging chemistry and speed-up their route to market. Research efforts in the Stradiotto group are directed toward developing new classes of ancillary ligands/transition metal complexes that exhibit interesting and unusual reactivity patterns, with the goal of incorporating such reactivity into synthetically useful catalytic substrate transformations that can be employed by end-users. Dr Carin Seechurn, associate director – technology solutions, Sinocompound, commented, “The licensing of these ligands from Dalhousie University helps to further strengthen the range of non-PGM catalysts offered by Sinocompound and will be hugely beneficial when working with customers to help develop their non-PGM-based processes. In today’s pharmaceutical industry, PGM chemistries provide a well-established solution, however, there can be a number of advantages to using non-PGM catalysts. These include the obvious potential cost savings over PGM catalysts, and in some cases, non-PGMs may offer solutions that can’t be achieved with PGM catalysts, such as a carbon-nitrogen bond formation reaction between a fluorinated amine and inexpensive aryl chlorides or phenol derivatives. For more insight into Sinocompound’s rationale behind the development and commercialization of non-PGM catalysts, please visit [https://bit.ly/non-pgm](https://bit.ly/non-pgm). About Sinocompound Sinocompound Catalysts Co., Ltd. is a global provider of advanced homogeneous catalysts and ligands for a range of pharmaceutical and fine chemical applications. The company’s proven process is built around cutting-edge technology, flexibility, and speed-of-response ensuring delivery at the scale required. Established partnerships across industry and academia enable the development of novel chemistry; helping customers accelerate their route to market. Established in 2008 and with headquarters in Zhangjiagang, China, Sinocompound focuses on listening to customers and delivering the high-quality catalyst technology and services they require – including homogeneous metal catalysts, ligands, and high-purity electronic and custom synthesis and catalyst screening services. [en.sinocompound.com](http://en.sinocompound.com) Categories: [Analytical Chemistry](https://news.lifesciencenewswire.com/newsroom/tag/analytical-chemistry), [General Chemistry](https://news.lifesciencenewswire.com/newsroom/tag/general-chemistry) ##### Browse more news ## Recent releases #### [Enhanced Compliance Inc. (ECI) Appoints Taranjit S. Samra as Head of Medical Device Software Enginee...](https://news.lifesciencenewswire.com/newsroom/enhanced-compliance-inc.-eci-appoints-taranjit-s.-samra-as-head-of-medical-device-software-engineering-cybersecurity-and-ai) July 6, 2026 Strengthens ECI’s AI & Digital Transformation capabilities to help clients develop the next generation of software-enabled medical technologies En... ##### [READ MORE](https://news.lifesciencenewswire.com/newsroom/enhanced-compliance-inc.-eci-appoints-taranjit-s.-samra-as-head-of-medical-device-software-engineering-cybersecurity-and-ai) #### [Alithea Genomics Launches Early Access Program for MERCURIUS™ 1536 DRUG-seq, Bringing Transcriptomic...](https://news.lifesciencenewswire.com/newsroom/alithea-genomics-launches-early-access-program-for-mercurius-1536-drug-seq-bringing-transcriptomics-to-compound-screening-scale) June 16, 2026 New ultra-high-throughput kit enables discovery teams to generate transcriptome-wide compound-response data directly from 1536-well plates Alithea Gen... ##### [READ MORE](https://news.lifesciencenewswire.com/newsroom/alithea-genomics-launches-early-access-program-for-mercurius-1536-drug-seq-bringing-transcriptomics-to-compound-screening-scale) #### [Arscience Biotherapeutics Appoints Gustavo Mahler as Chief Executive Officer](https://news.lifesciencenewswire.com/newsroom/arscience-biotherapeutics-appoints-gustavo-mahler-as-chief-executive-officer) June 16, 2026 Seasoned Biopharmaceutical Leader and Board Director Steps Up to Lead the Company’s Next Phase of Growth in Customized Interleukin Therapies ARScience... ##### [READ MORE](https://news.lifesciencenewswire.com/newsroom/arscience-biotherapeutics-appoints-gustavo-mahler-as-chief-executive-officer) ![LS-Newswire-reverse](https://news.lifesciencenewswire.com/hs-fs/hubfs/raw_assets/public/LifeScienceNewswire_June2020/images/LS-Newswire-reverse.png?width=150&name=LS-Newswire-reverse.png "LS-Newswire-reverse") Life Science Newswire is a division of BioStrata Ltd, with company registered address: 3rd Floor, 1 Ashley Road, Altrincham, Cheshire, England, WA14 2DT. Company registration number: 8233225  #### Useful information - [Cookie and privacy policy](https://lifesciencenewswire.com/cookie-privacy-policy/) - [Website terms and conditions](https://lifesciencenewswire.com/terms-and-conditions) - [Promotion terms and conditions](https://lifesciencenewswire.com/promotion_terms/)